Manuel Garcia Manero*

Department of Obstetrics and Gynecology, Hospital García Orcoyen, Calle Santa Soria, Spain

*Corresponding Author: Manuel Garcia Manero, Department of Obstetrics and Gynecology, Hospital García Orcoyen, Calle Santa Soria, Spain.

Received: October 4, 2022; Published: April 12, 2023

Abstract

Introduction: Uterine fibroids are a frequent pathology in women of reproductive age responsible for a variety of symptoms that can become disabling. Ulipristal Acetate is a medical treatment that causes a decrease in the size of the fibroid, improving symptoms. In this study we evaluated the correlation between the vascularization of the fibroid measured by ultrasound (Power Doppler 2D) and the levels of VEGF in serum, before and after treatment with ulipristal acetate in patients diagnosed with symptomatic uterine fibroids.

Material and Method: A prospective observational study was designed. Twenty-four premenopausal women, previously diagnosed with symptomatic uterine fibroids, were included and all completed the study. Four cycles of Ulipristal Acetate were administered according to the dose and indications specified in the data sheet. To assess the influence of this treatment on the fibroid angiogenesis process, serum VEGF levels were measured and its vascularization was assessed by 2d Power Doppler ultrasound; at the beginning and at the end of treatment. In addition, in successive visits several determinations of the same parameters were made. Parameters were defined as the decrease in VEGF levels from previous levels,

Results: 24 patients who met the inclusion criteria (n = 24) were recruited. The average size of the fibroids was reduced from 45.08 ± 24.02 mm to 29.00 mm-+-16.96 mm after treatment. The mean serum level of VEGF decreased significantly after the first cycle of treatment (from 147.17 ± 153.51 pg/mL to 102.04 ± 186.08 pg/ml). The vascularization of the fibroids was analyzed after treatment with Ulipristal Acetate, and a significant decrease was achieved in 83.3% of the cases.

Conclusions: There is a correlation between decreased vascularization of fibroids and treatment with Ulipristal Acetate. Selective Progesterone Receptor Modulators can provide effective treatment for women with symptomatic fibroids in two ways: by blocking selective progesterone receptor modulators and by reducing angiogenesis.

Keywords: Angiogenesis; Ulipristal Acetate; Uterine Fibroids; VEGF Doppler Ultrasound

References

1. Gupta S., et al. “Clinical Presentation of fibroids”. Best Practice and Research Clinical Obstetrics and Gynaecology 4 (2008): 615-626.
2. Olufowobi O., et al. “Are the anticipated benefits of myomectomy achieved in women of reproductive age? A five-year review of the results at a tertiary hospital”. Journal of Obstetrics and Gynecology 24 (2004): 434-440.
3. Donnez J and Dolmans MM. “Uterine fibroid management: from the present to the future”. Human Reproduction Update 6 (2016): 665-686.
4. Stovall DW., et al. “Clinical symptomatology of uterine leiomyomas”. Clinical Obstetrics and Gynecology 44 (2001): 364-371.
5. Esmya® 5 mg data sheet. Date of first authorization: February 23 (2012).
6. Donnez J., et al. “The place of selective progesterone receptor modulators in myoma therapy”. Minerva Ginecologica3 (2016): 313-320.
7. Rabe T., et al. “Selective Progesterone Receptor Modulators for the Medical Treatment of Uterine Fibroids with a Focus on Ulipristal Acetate”. Biomed Research International 2018 (2018): 1374821.
8. Mostafa A Borahay., et al. “Signaling Pathways in Leiomyoma: Understanding Pathobiology and Implications for therapy”. Molecular Medicine 21 (2015): 242-256.
9. Minah Kim., et al. “VEGF-A regulated by progesterone governs uterine angiogenesis and vascular remodeling during pregnancy”. EMBO Molecular Medicine 5 (2013): 1415-1430.
10. Juan Luis Alcázar and Manuel García Manero. “Ovarian endometrioma vascularization in women with pelvic pain”. Fertility and Sterility6 (2007).
11. Reshef Tal and James H Segars. “The role of angiogenic factors in fibroid pathogenesis: potential implications for future therapy”. Human Reproduction Update 2 (2014): 194-216.
12. Juan Luis Alcázar., et al. “Vascular endothelial growth factor (VEGF) and ovarian endometriosis: correlation between VEGF serum levels, VEGF cellular expression, and pelvic pain”. Fertility and Sterility2 (2007).
13. Czuczwar P., et al. “Influence of ulipristal acetate therapy compared with uterine artery embolization on fibroid volume and vascularity indices assessed by three-dimensional ultrasound: prospective observational study”. 45.6 (2015): 744-750.
14. Nieuwenhuis LL., et al. “Fibroid vascularization assessed with three-dimensional Power Doppler ultrasound is a predictor for uterine fibroid growth: a prospective study”. BJOG (2017).
15. Peng Yu., et al. “Progesterone‐mediated angiogenic activity of endothelial progenitor cell and angiogenesis in traumatic brain injury rats were antagonized by progesterone receptor antagonist”. Cell Proliferation5 (2017): e12362.
16. Anita Olejek., et al. “Long-term intermittent pharmacological therapy of uterine fibroids – a possibility to avoid hysterectomy and its negative consequences”. Prz Menopauzalny1 (2016): 48-51.

Citation

Citation: Manuel Garcia Manero. “Effect of Ulipristal Acetate on Uterine Fibroid Angiogenesis, Measured by 2D Power Doppler Ultrasound and Serum VEGF Levels". Acta Scientific Women's Health 5.5 (2023): 18-24.

Copyright

Copyright: © 2023 Manuel Garcia Manero. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.